By granting mutual recognition of products covered by free trade agreements with Canada and Korea, but which refuse to give the same treatment to products originating in the United Kingdom, the EU could violate WTO legislation. The EU-Australia AGREEMENT covers the following areas The mutual recognition agreement between the FDA and the European Union allows drug inspectors to rely on information from drug inspections carried out within the other country`s borders. Under the Drug Safety and Safety Act passed in 2012, the FDA has the authority to enter into agreements on the recognition of drug inspections by foreign regulators when the FDA has found that these authorities are able to conduct inspections in accordance with U.S. requirements. The FDA and the EU have been cooperating since May 2014 to assess how they control drug manufacturers and assess the risk and benefits of mutual recognition of inspections. Mutual recognition agreements aim to promote trade in goods between the EU and third countries by removing technical barriers by facilitating access to compliance assessment. As part of the bilateral agreement between governments, the importing country accepts the results of the compliance assessment, carried out by the notified compliance assessment bodies of the exporting country (CABs) – in order to demonstrate compliance with the requirements of the importing party. If the EU refuses to negotiate a similar system of mutual recognition with the UK, this may violate the most favoured nation obligation (MPF) under WTO law. The MFN is a non-discrimination rule that requires that any benefit granted to products originating in one country be granted to similar products originating in other countries. Restrictions: Capacity determination applies to routine inspections.
In the future, the following types of products and inspections may be included in the scope of the agreement, pending further considerations: mutual recognition agreements define the conditions under which a party (non-member) accepts the results of the compliance assessment (e.g.B.